Table 1

Baseline demographic and disease activity characteristics

All treatments n=1265SB4
n=250
ETN
n=228
SB2
n=213
INF
n=209
SB5
n=241
ADA
n=124
Age (years), mean (SD)51.3 (12.06)52.0 (11.76)50.7 (11.75)51.4 (12.17)52.0 (11.55)49.8 (12.69)52.8 (12.46)
Gender, n (%)1032 (81.6)210 (84.0)194 (85.1)168 (78.9)169 (80.9)191 (79.3)100 (80.6)
Disease duration (years), mean (SD)5.9 (4.91)5.8 (4.14)5.8 (4.34)6.3 (6.01)6.6 (5.81)5.3 (4.35)5.6 (4.52)
MTX dose at baseline (mg/week), mean (SD)15.2 (4.39)15.7 (4.44)15.7 (4.56)14.65 (4.12)14.8 (3.94)15.1 (4.65)15.2 (4.51)
Swollen joint count (0–66), mean (SD)15.1 (7.51)15.3 (7.27)14.9 (7.25)14.1 (6.87)14.5 (7.40)15.7 (8.02)16.3 (8.42)
Tender joint count (0–68), mean (SD)23.7 (11.91)23.6 (11.84)23.3 (12.33)23.9 (12.40)23.9 (11.67)23.8 (11.82)24.1 (11.10)
HAQ-DI (0–3), mean (SD)1.45 (0.588)1.50 (0.545)1.50 (0.561)1.47 (0.598)1.52 (0.578)1.34 (0.597)1.35 (0.665)
DAS28 (ESR), mean (SD)6.5 (0.82)6.5 (0.91)6.5 (0.89)6.5 (0.77)6.5 (0.78)6.5 (0.75)6.4 (0.78)
CDAI, mean (SD)38.4 (11.31)38.4 (12.21)38.1 (11.47)37.8 (10.52)38.6 (11.08)39.1 (11.08)38.5 (11.40)
SDAI, mean (SD)39.7 (11.64)39.9 (12.65)39.4 (11.72)39.0 (10.74)40.0 (11.43)40.3 (11.55)39.7 (11.57)
Physician Global Assessment VAS (0–100), mean (SD)61.7 (15.45)62.5 (14.93)63.2 (14.94)61.3 (14.92)61.5 (15.20)60.1 (16.70)61.1 (16.19)
Patient Global Assessment VAS (0–100), mean (SD)61.7 (18.39)62.2 (18.62)63.5 (16.81)62.3 (16.67)63.2 (18.01)58.6 (20.35)60.0 (19.63)
Patient pain assessment VAS (0–100), mean (SD)61.8 (19.35)62.9 (19.71)62.1 (18.92)61.3 (17.42)63.5 (19.62)59.6 (20.37)60.9 (19.93)
C reactive protein (mg/L), mean (SD)12.9 (18.90)14.8 (20.79)12.5 (16.08)12.0 (18.72)14.0 (20.42)11.6 (19.54)11.9 (15.79)
Erythrocyte sedimentation rate (mm/hour), mean (SD)43.8 (19.61)45.6 (22.14)45.9 (22.55)43.9 (18.50)46.2 (21.54)39.8 (13.77)39.4 (14.15)
Rheumatoid factor positive, n (%)951 (75.2)199 (79.6)181 (79.4)152 (71.4)148 (70.8)181 (75.1)90 (72.6)
Modified Total Sharp Score
(0–448), mean (SD)
37.1 (56.36)43.3 (67.08)38.9 (53.26)37.1 (57.53)38.9 (56.27)29.8 (46.74)32.9 (52.61)
  • ADA, adalimumab reference product; CDAI, Clinical Disease Activity Index; DAS28, disease activity score based on 28-joint count; ESR, erythrocyte sedimentation rate; ETN, etanercept reference product; HAQ-DI, Health Assessment Questionnaire Disability Index; INF, infliximab reference product; MTX, methotrexate; SB2, biosimilar of infliximab; SB4, biosimilar of etanercept; SB5, biosimilar of adalimumab; SDAI, Simplified Disease Activity Index; VAS, visual analogue scale.